Published in Lancet on April 29, 2000
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol (2015) 2.99
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol (2016) 1.45
Hormonal therapy in the elderly prostate cancer patient. Dtsch Arztebl Int (2009) 1.38
Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol (2007) 1.36
Synchronous testicular liposarcoma and prostate adenocarcinoma: a case report. Cases J (2010) 1.33
Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol (2013) 1.23
Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol (2009) 1.20
The biology and treatment of oligometastatic cancer. Oncotarget (2015) 1.08
Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol (2011) 1.06
Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol (2007) 1.05
Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol (2010) 1.04
Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci U S A (2003) 1.01
Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl (2012) 0.98
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct (2010) 0.97
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist (2010) 0.94
Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. Proc Natl Acad Sci U S A (2011) 0.92
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget (2016) 0.92
Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int (2008) 0.92
Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol (2008) 0.90
Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol (2014) 0.89
Maximum androgen blockade: a clinical update. Rev Urol (2005) 0.89
Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer (2015) 0.89
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Cent European J Urol (2016) 0.88
Effects of endocrine disruptors on prosobranch snails (Mollusca: Gastropoda) in the laboratory. Part III: Cyproterone acetate and vinclozolin as antiandrogens. Ecotoxicology (2001) 0.87
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol (2010) 0.85
Hormonal therapy for prostate cancer. Rev Urol (2006) 0.85
SEOM clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol (2014) 0.83
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther (2013) 0.83
Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol (2008) 0.83
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther (2015) 0.83
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol (2008) 0.81
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol (2012) 0.81
Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol (2006) 0.81
Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. BMC Cancer (2015) 0.81
Management of advanced prostate cancer in senior adults: the new landscape. Oncologist (2012) 0.81
Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer. World J Urol (2015) 0.81
Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. Front Oncol (2013) 0.80
Hormonal therapy in prostate cancer: historical approaches. Rev Urol (2004) 0.80
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. ACS Med Chem Lett (2015) 0.80
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis. Prostate Int (2015) 0.79
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer (2016) 0.79
Hormone therapy in the management of prostate cancer: evidence-based approaches. Ther Adv Urol (2010) 0.79
The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy? Asian J Androl (2012) 0.79
Choice of hormonal therapy for prostate cancer. Lancet (2000) 0.78
Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression. Oncoimmunology (2013) 0.78
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol (2003) 0.78
A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. Int J Clin Oncol (2006) 0.78
Treatment options for hormone-refractory prostate cancer. Rev Urol (2007) 0.78
Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc (2012) 0.78
Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis. Asian J Androl (2015) 0.78
A critical review of maximal androgen blockade for advanced prostate cancer. Rev Urol (2004) 0.78
Saudi Oncology Society clinical management guidelines for prostate cancer. Urol Ann (2011) 0.78
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre. Asian J Androl (2010) 0.78
Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score. Prostate Int (2013) 0.78
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Can Urol Assoc J (2009) 0.76
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol (2003) 0.76
Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget (2016) 0.76
[Current treatment of locally advanced and metastatic prostate cancer]. Wien Med Wochenschr (2011) 0.76
Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int (2015) 0.76
What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care? J Cancer Res Clin Oncol (2006) 0.76
The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. J Cancer Res Clin Oncol (2014) 0.75
Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. J Cancer Res Clin Oncol (2014) 0.75
Oligometastatic Prostate Cancer. Curr Treat Options Oncol (2016) 0.75
Risk stratification in the hormonal treatment of patients with prostate cancer. Ther Adv Med Oncol (2009) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urol Ann (2016) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urol Ann (2014) 0.75
Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine (Baltimore) (2016) 0.75
Role of maximum androgen blockade in advanced prostate cancer. Indian J Urol (2009) 0.75
Hormonal therapy in metastatic prostate cancer: current perspectives and controversies. Oncol Rev (2013) 0.75
Paradoxical response of prostate cancer skeletal metastases to androgen deprivation therapy. Radiol Case Rep (2015) 0.75
Diagnosis and treatment of gastrointestinal stromal tumor extending to prostate: A case report and literature review. Medicine (Baltimore) (2016) 0.75
The course of metastatic prostate cancer under treatment. Springerplus (2014) 0.75
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. Ther Adv Urol (2015) 0.75
Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol (2016) 0.75
Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer. Intern Med (2016) 0.75
Chlormadinone acetate is effective for hot flush during androgen deprivation therapy. Prostate Int (2013) 0.75
Maximal androgen blockade for advanced prostate cancer. Indian J Urol (2010) 0.75
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci (2016) 0.75
What determines testosterone levels? Can Urol Assoc J (2012) 0.75
Recombinant disintegrin domain of human ADAM9 inhibits migration and invasion of DU145 prostate tumor cells. Cell Adh Migr (2015) 0.75
Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate. Clin Med Oncol (2008) 0.75
Challenges with luteinizing hormone-releasing hormone agonists: flare and surge. Rev Urol (2004) 0.75
Androgen blockade in prostate cancer. Lancet (2000) 0.75
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget (2016) 0.75
Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol (2001) 0.75
Endocrine manipulations in cancer prostate: A review. Indian J Endocrinol Metab (2012) 0.75
Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. Res Rep Urol (2016) 0.75
Prostate cancer pathology, screening, and epidemiology. Rev Urol (2001) 0.75